A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This research study is studying the combination of anakinra and axicabtagene ciloleucel to
reduce the occurrence of the side effects Cytokine Release Syndrome (CRS) and neurologic
toxicities with relapsed or refractory Non-Hodgkin lymphoma (NHL).
- Relapsed NHL is the condition of returned Non-Hodgkin lymphoma.
- Refractory NHL is the condition of previous treatment resistant Non-Hodgkin lymphoma.
- Cytokine Release Syndrome (CRS) is a group of side effect symptoms that can include
nausea, headache, rapid heartbeat, shortness of breath, kidney damage, and rash.
- Neurologic toxicity is nervous system disorder characterized by confusion
This research study involves two drugs:
- Anakinra
- Axicabtagene Ciloleucel.